Monday 23 May
ESC/EAS joint session: A deep dive into Prevention GLs with focus on dyslipidemia
- Alberico Catapano
Alberico CatapanoMilan, Italy
Full Professor of Pharmacology, Director of the Center of Epidemiology and Preventive Pharmacology (SEFAP) as well as Director of the Laboratory of Lipoproteins, Immunity and Atherosclerosis at the University of Milan (Department of Pharmacological and Biomolecular
Sciences) and PhD coordinator from 2017 to 2020.
Moreover he is Director of the Center for the Study, Prevention and Therapy of Atherosclerosis of the University of Milan, at the Bassini Hospital, Head of Cardiovascular Research Line at Multimedica IRCCS Sesto San Giovanni (Mi), President of the Italian Society of Clinical and Sperimental Therapy (SITeCS) and General Director of the SISA Foundation
His main research, from 1972, interests include the study of atherosclerosis, lipids, lipoproteins and genetic dyslipidaemias, and he has made landmark observations regarding heat shock proteins and pentraxins in atherogenesis, on high-density lipoproteins in the modulation of the immune response, and on the identification of possible therapeutic targets by exploiting genetic information. Past President of the European Atherosclerosis Society (EAS), Professor Catapano is currently Co- Chairman of the EAS/European Society of Cardiology (ESC) guidelines for the treatment of dyslipoproteinaemias. Editor of Atherosclerosis Supplements, Co-editor of Atherosclerosis and Associate Editor of other scientific journals, he has authored more than 590 scientific papers in peer-reviewed journals (I.F. 10.929) and is among the highly cited scientists in 2019, 2020 and 2021 according to Clarivate
- Francois Mach
Francois MachGeneva, Switzerland
Prof. François Mach is full Professor of cardiology at Geneva University Hospital and head of Cardiology Department since 2006. He completed a post-doctoral fellowship in the laboratory of Prof. Peter Libby, Brigham and Women’s Hospital, Boston (1995-1999). Between 2012-14, he was the President of the Swiss Society of Cardiology. He is the author of more than 500 high impact factor publications. As director of the atherosclerosis basic science laboratory, he and his research group have substantially contributed to a better clarification of the inflammatory mechanisms underlying atherosclerosis and its acute complications, both in human cohorts and animal studies. For several years now, he has also been strongly implicated in clinical research in the field of prevention, especially lipidology, by contributing to the design and completion of several clinical research projects and multi-center studies. He is also responsible of several Swiss cohorts of atherothrombotic patients, and is one of the 3 co-chairs of the ESC/EAS 2019 Lipid Guidelines, as well as co-chair of the ESC 2021 Prevention Guidelines.
Michal Vrablik, Praha 2, Czech Republic
Praha 2Czech Republic
Michal Vrablik M.D., Ph.D. is a Professor of Internal Medicine at the 1st Faculty of Medicine, Charles University in Prague, the Czech Republic. His main interests include preventive cardiology, clinical lipidology, CVD risk reduction strategies.
He is the chairman of the Czech Atherosclerosis Society, member of board of the Czech Society of Internal Medicine and the chairman of the Czech Association of Preventive Cardiology of the Czech Society of Cardiology. He is the head of the National centre of the FH screening MedPed program.
He served as a member of the Executive Committee of the European Atherosclerosis Society between 2012 and 2016.He closely cooperates with the International Atherosclerosis Society being the chair of IAS Regional Federation for Europe since January 2019. Since 2010 Dr. Vrablik has co-organized International Atherosclerosis Research School endorsed by the EAS and IAS.
Dr. Vrablik has authored and co-authored more than 400 papers in peer-reviewed scientific journals. He is the sole author of three monographs and of 25 book chapters. He is also a member of editorial board as well as a reviewer for several national and international journals.
Ian Graham, Ireland
Brian Ference, Cambridge, United Kingdom
Ulrich Laufs, Leipzig, Germany
Monday 23 May
IAS/EAS joint session - What is the environment doing to our health?
- Stefano Romeo
- Raul Santos
Raul SantosSão Paulo, Brazil
Raul D. Santos MD, PhD, MSc is Director of the Lipid Clinic of the Heart Institute (InCor) and associate professor at the Cardiopneumology Department the University of São Paulo Medical School, Brazil. He is the clinical coordinator of the “Hipercol Brasil” Familial Hypercholesterolemia (FH) Genetic Cascade Screening Program. He is also Researcher at the Academic Research Organization of the Hospital Israelita Albert Einstein in São Paulo. After completing his training in cardiology Dr. Santos obtained master and PHD degrees in food science at the University of Sao Paulo. His research interests include lipid metabolism, severe forms of genetic dyslipidemias, especially familial hypercholesterolemia and HDL deficiency, non-alcoholic fatty liver disease, imaging in atherosclerosis focusing on detection of vascular calcification and novel therapies for dyslipidemias. He is a past president of the International Atherosclerosis Society (IAS). In 2021 he was qualified as a Highly Cited Researcher (0.1% top researchers) in the field of Cross-Field by Clarivate Analytics.
Ruth Loos, Copenhagen, Denmark
Ruth Loos is Vice Executive Director and Group Leader of the Novo Nordisk Foundation Center for Basic Metabolic Research (CBMR) at the University of Copenhagen, and part-time professor at the Icahn School of Medicine at Mount Sinai in New York. She has almost two decades of experience in researching the genetic causes of obesity. As a founding member of the GIANT (Genetic Investigation of ANTropometric traits) consortium, she has pioneered many of the large-scale gene-discovery efforts that have thus far identified more than 1,000 obesity-associated loci.
She has a particular interest in studying more refined adiposity phenotypes, composite phenotypes (of multiple adiposity-related traits) and subtypes of obesity to reveal new biology that has not been uncovered by traditional obesity outcomes. Ruth collaborates with bioinformaticians, molecular biologists and physiologists to bridge the translation gap from variant to function.
As more and more GWAS loci are being discovered, she examines whether genotype information can be used to identify subtypes of obesity, to predict who is at risk of becoming obese or to prescribe tailored prevention and treatment strategies in the context of precision diagnosis, prevention and treatment.
Sanjay Rajagopalan, Cleveland, USA
Dr. Sanjay Rajagopalan is the Chief of Cardiovascular Medicine, University Hospitals Harrington Heart and Vascular Institute, Herman Hellerstein, MD Professor of Cardiovascular Research and Director of the Case Cardiovascular Research Institute at Case Western Reserve School of Medicine, Cleveland, OH. Dr. Rajagopalan is among an elite group of physician scientists whose work has help transform global perceptions and understanding of the impact of environmental risk factors on cardiovascular disease. He has additionally made seminal contributions towards the development of next generation therapeutic modalities for cardiovascular disease and is a leading authority in advancing innovative approaches for the imaging of complex cardiovascular disorders. Dr. Rajagopalan’s laboratory has been continually funded by the National Institutes of Health (NIH). Dr. Rajagopalan is an elected member of the American Society of Clinical Investigation (ASCI), American Association of Physicians (AAP), Association of University Cardiologists (AUC), the Association of Professors of Cardiology (APC) and is the recipient of the American College of Cardiology’s Distinguished Scientist Award (Translational Domain). Dr. Rajagopalan has published over than 400 original peer reviewed research publications in journals such as JAMA, New England Journal of Medicine, Circulation, Journal of Clinical Investigation and Circulation Research in addition to more than 300 invited editorials and reviews. He has served as an editor for at least two textbooks and several monographs on vascular disease and atherosclerosis.
Thomas Münzel, Germany
Khurram Nasir, Houston, USA
Tuesday 24 May
NLA/EAS joint session - Primordial prevention: The neglected topic
- Kausik Ray
Kausik RayLondon, United Kingdom
Kausik Ray is currently Professor of Public Health, Deputy Director of Imperial Clinical Trials Unit and Head of Commercial Trials within the Department of Public Health and Primary Care, School of Public Health, Imperial College London, Consultant Cardiologist and Chief Clinical Officer and Head of Trials –Discover Now as well as NIHR ARC National Lead of Cardiovascular Disease. Professor Ray received his medical education (MB ChB, 1991) at the University of Birmingham Medical School, his MD (2004) at the University of Sheffield, a post-doctoral fellowship at Harvard Medical School and finally an MPhil in epidemiology (2007) from the University of Cambridge.
A Fellow of the American College of Cardiology, the European Society of Cardiology, the American Heart Association and the Royal College of Physicians, Kausik Ray is also a member of the British Cardiovascular Society and President of the European Atherosclerosis Society, also serving on the EAS Consensus panel and EAS Executive Committee. Professor Ray has either been the National Lead Investigator, Principal Investigator, or served on committees for several major medical trials, as well as international registries and is currently involved in 8 ongoing trials in lipids and diabetes and the PI for ORION 1, 3, 11 assessing PCSK9 inhibition through RNA interference and BETONMACE assessing BET protein inhibition in patients with ACS.
Professor Ray’s research interests have focused on the prevention of coronary disease with a focus on lipids, diabetes, biomarkers and risk prediction. He has an H index of 87, an i10 of 220 and over 92,000 citations for his work in journals such as New England Journal of Medicine, The Lancet, JAMA, European Heart Journal, Circulation and JACC. He has also been included in the Clarivate Analytics’ list of the top 1% most cited authors in all of global medicine in 2018, 2019 and 2020. Key original contributions which have influenced European and American guidelines include demonstrating the early benefits of statin therapy post ACS, the impact of more/less intensive glycaemic control on CVD and the risks/benefits of aspirin therapy in primary prevention. Recently, his work on statins and diabetes risk led to a global label change for statins by the FDA and EMEA. Currently Professor Ray leads the EAS FH Studies collaboration which is the first global registry of FH which includes 70 countries and 62,000 cases, as well as being the Senior PI for the TOGETHER study looking at cardiometabolic risk in the vascular health checks in 250,000 people in London.
- Joseph Saseen
Joseph SaseenAurora, USA
Joseph Saseen, PharmD, is Associate Dean for Clinical Affairs and Professor of Clinical Pharmacy and a Professor of Family Medicine. He also served as Vice Chair of the Department of Clinical Pharmacy for 10 years.
Dr. Saseen is President of the National Lipid Association (NLA). He is a fellow of the American College of Clinical Pharmacy, American Society of Health-system Pharmacists, American Pharmacists Association, the American Heart Association, and the NLA. He is board certified as a Pharmacotherapy Specialist and an Ambulatory Care Pharmacists, and is a certified as a Clinical Lipid Specialist.
Dr. Saseen has responsibilities for enhancing the school’s clinical enterprise, further developing sustainable clinical service models, and advocating for advancing the practice of pharmacy in the State of Colorado. He is a clinical pharmacist at the University of Colorado Health focusing on cardiovascular risk reduction and population health. Dr. Saseen teaches cardiovascular pharmacotherapy and other topics related to primary care, and is the PGY2 Ambulatory Care residency program director. His scholarly work includes almost 200 peer-reviewed publications and book chapters.
Mai-Lis Hellenius, Stockholm, Sweden
Mai-Lis Hellénius, MD, Ph.D., professor in cardiovascular prevention at the Karolinska Institutet, Stockholm, Sweden.
Mai-Lis Hellénius was born 1953. MD at Karolinska Institutet 1978. Certified specialist in Family Medicine 1985. In 1995 Mai-Lis Hellénius defended her thesis “Prevention of cardiovascular disease – Studies on the role of diet and exercise in the prevention of cardiovascular disease among middle aged men.” The thesis was based on a controlled randomized trial and thereby she was among the first in the world to scientifically evaluate advice on lifestyle. Associate professor in 1999. Professor in cardiovascular prevention focusing lifestyle in 2006.
She has for more than 40 years been working both as a clinician, a researcher and a teacher in the area of lifestyle medicine. She was among the first physicians in the world initiating physical activity on prescription in 1987. Mai-Lis Hellénius has 260 publications and 169 of them are publications in peer review journals.
Mai-Lis Hellénius has been the tutor of 16 Ph.D. students who have defended their thesis. All Ph.D. projects have focused physical activity, lifestyle and prevention. She has been engaged in the writing of national and Nordic guidelines for diet and physical activity as well as prevention of cardiovascular disease. She is a member of many expert committees both nationally and internationally and she has been invited speaker at international meetings more than 100 times. Mai-Lis Hellenius has served as a faculty opponent on 36 occasions of both Swedish and international universities. She has been awarded in Sweden and from several international universities. Year 2017 she was invited to give the Morris-Paffenbarger Honorary lecture at the opening session of American College of Sports Medicine meeting in Denver, USA.
She has written several textbooks in lifestyle medicine and cardiovascular prevention for the professional audience. She has also developed a web-based educational program for health care professionals as well as the public, which was launched in 2009 from the Karolinska Institutet (www.sundkurs.se). She is a requested lecturer for professional as well as for the public.
Mai-Lis Hellénius has also written several popular science books on nutrition, physical activity and a healthy lifestyle. Several of them have been awarded in Sweden and internationally. Mai-Lis Hellénius received the Dun Gifford’s Award from Gourmand International Cookbook Awards for one of the books. The books “Vitally important” about lifestyle and health and Vitally important-the Cookbook, won the Gourmand International Cookbook Award in 2017 and 2019. In 2021 the book Vitally important was awarded as the Best during 25 years in its category and a new book about health for seniors also won a prize the Gourmand Cookbook International Award.
Anne Carol Goldberg, Saint Louis, USA
Anne Carol Goldberg
Anne Carol Goldberg, MD, FACP, FAHA, FNLA is an endocrinologist and lipid specialist. She received her medical degree from University of Maryland and completed internal medicine residency at Michael Reese Hospital, Chicago, Illinois, and endocrinology fellowship at Washington University School of Medicine, St. Louis, Missouri, where she is now Professor of Medicine. Research interests include therapies for hyperlipidemia and the treatment of familial hypercholesterolemia. She has conducted clinical trials involving most classes of lipid-modifying drugs. She treats adults and children with dyslipidemia, including familial hypercholesterolemia, and has a lipoprotein apheresis program. Awards include the National Forum for Heart Disease and Stroke Prevention Public Policy Award, the Foundation of the National Lipid Association Clinician/Educator Award, and Washington University School of Medicine Distinguished Clinician Award.
She is a past President of the National Lipid Association (NLA) and immediate past president of the Foundation of the NLA. She chaired the NLA Expert Panel on Familial Hypercholesterolemia and was a member of the ACC/AHA Blood Cholesterol Expert Panel for the 2013 ACC/AHA Cholesterol Guidelines and of the task force for the Endocrine Society Clinical Practice Guideline on Evaluation and Treatment of Hypertriglyceridemia. She is currently the Chief Science Officer of the NLA.
Kevin Maki, Addison, USA
Kevin C Maki, PhD is the Founder and Chief Scientist for Midwest Biomedical Research (Chicago, Illinois) and MB Clinical Research (Bonita Springs, Florida), divisions of MB Clinical Research and Consulting, LLC. He specializes in the design and conduct of clinical studies in human nutrition, metabolism, and chronic disease risk factor management. Dr Maki is also Adjunct Professor and Dean’s Eminent Scholar in the Department of Applied Health Science at the Indiana University School of Public Health, Bloomington, Indiana. He is a Fellow of the National Lipid Association, The Obesity Society, and the American College of Nutrition, as well as a certified Clinical Lipid Specialist. He is past President of the Board of Governors for the Accreditation Council for Clinical Lipidology and is President-elect of the National Lipid Association. Dr. Maki is also an inaugural member of the Statistical Review Board of the American Society for Nutrition.
Dr. Maki has participated in more than 300 clinical trials and observational studies as an investigator, consultant, or statistician, and published more than 300 scientific papers, books, and book chapters. He earned a PhD in Epidemiology from the University of Illinois at Chicago’s School of Public Health, and an MS in Preventive and Rehabilitative Cardiovascular Health from Benedictine University.
Lale Tokgözoğlu, Ankara, Turkey
S. Lale Tokgözoğlu, MD, FACC, FESC is Professor of Cardiology at Hacettepe University, Ankara, Turkey. She is currently the immediate Past-President of the European Atherosclerosis Society and Deputy Editor of the European Heart Journal. She chaired the ‘Atherosclerosis and Vascular Biology Working Group of the European Society of Cardiology’ between 2008 and 2010. Prof. Tokgözoğlu has served on the Board of the Turkish Society of Cardiology and was elected to be the first female President of the Society in its history, between 2014-2016. During that time, she worked with the Ministry of Health to develop ‘Heart Health policies’ and strategies. She also chaired the Dyslipidaemia Working Group of the Turkish Society of Cardiology. She has contributed to several Guidelines and Consensus Papers on dyslipidaemia and Preventive Cardiology both in Europe and nationally. She was a member of the Steering Committee of the EUROASPIRE III-V studies which were the landmark studies defining preventive measures in Europe. She has also served on the Board of the Prevention Association as well as different committees of the European Society of Cardiology including the Fellowship and Training Committee, the Education Committee and currently the Research and Grants Committee. She is a member of the Science Academy and a founding member of the Atherosclerosis Research and Education Society in Turkey. She is also a founding member of the Department of Noncommunicable diseases in Hacettepe University. She serves on the Scientific and Research Council of Turkey Working Group on women researchers.
Metrodora Award Global Leader in Science and Health 2020
Istanbul Medical Association Science Award in 2019
Paul Dudley White Science team award AHA 2017
Prof. Dr. Şeref Zileli Resident of the Year” Award in 1987
Young Investigator Award of the Turkish Society of Cardiology in 1994